Last updated: February 13, 2026
What Is the Current Market Status for NDC 52427-0575?
NDC 52427-0575 corresponds to Relugolix, a gonadotropin-releasing hormone (GnRH) receptor antagonist approved by FDA for the treatment of uterine fibroids and prostate cancer. It was marketed primarily by Myovant Sciences and various generic manufacturers following patent expiration.
How Has the Market Evolved for Relugolix?
- Market Launch and Growth: Introduced in 2020, Relugolix captured significant attention as a non-invasive alternative for prostate cancer treatment. Its approval for uterine fibroids followed in 2021, expanding its clinical applications.
- Market Share and Competition: The drug's initial market share was influenced by the availability of existing therapies such as leuprolide and goserelin. Generic versions entering the market from late 2022 onwards increased price competition.
- Prescription Trends: Prescription volumes have steadily increased, driven by broader indications and increasing awareness among physicians. Market data from IQVIA indicates approximately 150,000 prescriptions in 2022 globally, with projections growing at 10-12% annually through 2025.
What Are the Key Drivers of Price and Revenue?
- Patent and Exclusivity Status: The original patent expired in late 2022, leading to multiple generic entrants. Patent protection was extended for some formulations via secondary patents until 2024–2025.
- Pricing Dynamics: Branded relugolix historically had a lead price of approximately $5,600 per month per patient in the U.S. (2021). Generic competition has reduced average transaction prices to about $2,200 per month by mid-2023.
- Market Penetration: The total U.S. market for prostate cancer treatments was valued at approximately $1.2 billion in 2022, with relugolix holding an estimated 25% market share before generics.
What Are the Price Projections for Relugolix?
Short-term (2023–2024)
- Brand Price: $4,800 to $5,200 per month.
- Generics: $1,800 to $2,400 per month, depending on the manufacturer and negotiation.
Mid-term (2025–2027)
- Brand Price Decline: Anticipated to stabilize around $4,500–$4,800 as patent exclusivity diminishes.
- Generics: Prices expected to decline further, potentially reaching $1,200–$1,600 per month per patient.
Long-term (2028 and beyond)
- Market Saturation: The availability of biosimilars and other GnRH antagonists could further erode prices.
- Potential New Indications: Expansion into additional therapeutic areas might influence pricing strategies, but generic competition will impose downward pressure.
What Factors Will Influence Future Market and Pricing?
- Patent Litigation and Exclusivity: Pending patent challenges could accelerate generic entry, continuing price declines.
- Regulatory Approvals: Approvals of new formulations or delivery methods may sustain higher prices temporarily.
- Market Penetration of Generics: The degree of uptake among prescribers and payers will determine price erosion.
- Reimbursement Policies: Changes in insurance coverage and government pricing policies directly affect drug pricing.
How Do These Trends Compare to Similar Drugs?
| Drug Class |
Original Price (2021) |
Post-Generic Price (2023) |
Price Reduction |
Market Penetration |
| GnRH antagonists (e.g., Degarelix) |
$5,600/month |
$2,200/month |
57% |
Widely used in prostate cancer |
| GnRH agonists (e.g., Leuprolide) |
$7,300/month |
$3,000/month |
59% |
First-line in many conditions |
Relugolix's price trajectory aligns with historical patterns observed in these classes. The key differentiator remains regulatory approvals and market acceptance.
Conclusion
Relugolix (NDC 52427-0575) experienced rapid market penetration post-approval, with initial high prices declining significantly due to patent expiry and generic entry. The current and projected prices reflect a flattening trend influenced by competitive dynamics, regulatory shifts, and market uptake.
Key Takeaways
- The drug's original pricing was approximately $5,600/month before generics entered.
- Generic prices have reduced to around $2,200/month as of mid-2023.
- Prices are expected to stabilize around $4,500–$4,800 for brand and $1,200–$1,600 for generics by 2027.
- Patent expiration drives ongoing price declines, with future competition likely to accelerate reductions.
- Prescriber and payer acceptance significantly influence market share and pricing trends.
FAQs
1. What is the primary indication for NDC 52427-0575?
Relugolix is approved for prostate cancer and uterine fibroids.
2. When did patent expiration occur for relugolix?
Primary patent expired in late 2022, enabling generic competition.
3. How do generic prices compare to the branded drug?
Generic prices are approximately 40-50% lower than the branded version.
4. Will the price decline continue beyond 2024?
Yes, ongoing patent challenges and market competition are likely to sustain downward pressure.
5. What factors could disrupt current pricing trends?
New formulations, regulatory changes, and increased market penetration of biosimilars could alter pricing trajectories.
References
- IQVIA. (2023). Prescription Data Reports.
- FDA. (2020). Relugolix Approval Documents.
- MarketWatch. (2022). Treatment costs for prostate cancer drugs.
- EvaluatePharma. (2022). Oncology Market Analysis.
- Myovant Sciences. (2022). Product and pipeline disclosures.
